Clinical trials: Levodopa
Parkinson's Disease
Pharmacokinetic Study in Healthy Volunteers
Phase I open, randomized cross-over pharmacokinetic study.
- Trial name
- NOCOFPK2 (NCT02554734)
- Testing
- levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone
- Where
- Finland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson Disease
Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics
To investigate the effect of four single oral doses of BIA 6-512 (25 mg, 50 mg, 100 mg and 200 mg) on levodopa pharmacokinetics when administered in combination with a single-dose of controlled release levodopa/benserazide 100/25…
- Trial name
- NCT03091543
- Testing
- Madopar® HBS 125, BIA 6-512 25 mg dose, BIA 6-512 50 mg dose
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics
To investigate the effect of rising oral single-doses of BIA 6-512 (25 mg, 50 mg, 100 mg and 200 mg) on levodopa pharmacokinetics when administered in combination with a single-dose of immediate release levodopa/carbidopa 100/25…
- Trial name
- NCT03091868
- Testing
- Sinemet® 100/25, Comtan®, BIA 6-512 25 mg
- Where
- Portugal
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
The purpose of this study is assess the safety and bioequivalence of a single oral dose of carbidopa+levodopa+entacapone combination versus a single oral dose of carbidopa+levodopa combination plus a single oral dose of…
- Trial name
- NCT00415922
- Testing
- ELC200 (carbidopa+levodopa+entacapone)
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novartis
Parkinson Disease
WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects
The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics
- Trial name
- NCT04513340
- Testing
- WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
- Where
- India
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
Other
Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)
This will be a single center, bioequivalence and food-effect, open-label study designed to be conducted in three sequential parts:
- Trial name
- NCT04236921
- Testing
- DopaSnap®, RDL of CD-LD
- Where
- Canada
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Riverside Pharmacueticals Corporation
Parkinson's Disease
Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611
The study hypothesis is that continuous ND0611 increases the bioavailability of levodopa and therefore the levodopa area-under-the-concentration-curve values, half-life, and trough concentrations The study will help determining…
- Trial name
- NCT01103011
- Testing
- ND0611
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.
Parkinson's Disease
A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects
The purpose of this clinical research study is to determine if different dosage regimens of Sinemet® CR (Carbidopa/levodopa) are dose proportional
- Trial name
- NCT00460954
- Testing
- Sinemet® controlled release (Carbidopa/levodopa)
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Parkinson Disease
Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
To investigate the pharmacokinetics of levodopa when administered concomitantly with BIA 9-1067 or 1 hour after.
- Trial name
- NCT01533077
- Testing
- BIA 9-1067, Sinemet® 100/25 mg
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Fasted State
Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration
The study is carried-out to describe and compare the plasma pharmacokinetics of levodopa and carbidopa after oral single-dose administration of 100 mg levodopa plus 25 mg carbidopa by means two fixed combination products (test…
- Trial name
- LCD18K (NCT02116465)
- Testing
- Levodopa Carbidopa immediate release tablets
- Where
- Bulgaria
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Desitin Arzneimittel GmbH
Parkinson's Disease
Levodopa Concentration Profile With Stalevo 75/125 mg
The purpose of this study is to confirm that the dose levels and dosing frequency utilising the new Stalevo strengths would result into more stable levodopa plasma levels.
- Trial name
- NEWSTA (NCT01070628)
- Testing
- Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa)
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
It will be a single dose, single-center, randomized, double-blind, placebo-controlled dose escalation study of SC continuously-delivered LD/CD solution (ND-0612) for 24 hours in healthy volunteers. Objectives are to determine: 1.
- Trial name
- NCT01486628
- Testing
- ND0612
- Where
- Israel
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- NeuroDerm Ltd.
Parkinson Disease
A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
This study will be an open-label, randomized, three-period cross-over pharmacokinetic evaluation of CVT-301 compared with the Reference Listed Drug (RLD), orally administered carbidopa/levodopa, in healthy volunteers.
- Trial name
- NCT02812394
- Testing
- CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Acorda Therapeutics
Parkinson's Disease
Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)
The purpose of this study is to investigate the tolerability, pharmacokinetic profile of BIA 3-202 and its metabolites, and the pharmacokinetic and pharmacodynamic interaction between 4 different single doses of BIA 3-202 (50 mg…
- Trial name
- NCT02763852
- Testing
- BIA 3-202, Madopar® 125
- Where
- Portugal
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease (PD)
Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
The purpose of this study is to determine the effect of BIA 9 1067 (5 mg, 15 mg and 50 mg) in steady-state conditions on the levodopa pharmacokinetics of a single dose of immediate-release levodopa/carbidopa 100/25 mg and of a…
- Trial name
- NCT02169414
- Testing
- BIA 9-1067 5 mg, BIA 9-1067 25 mg, levodopa/carbidopa 100/25
- Where
- France
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
To investigate the effect of repeated dosing of BIA 9-1067 on the levodopa pharmacokinetics, in comparison to placebo and entacapone.
- Trial name
- NCT01519284
- Testing
- BIA 9-1067 5 mg, Entacapone, levodopa/carbidopa
- Where
- Portugal
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa/carbidopa 100/25 mg…
- Trial name
- NCT02169453
- Testing
- BIA 9-1067, Sinemet® CR 100/25
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy Volunteers
Dose-finding Pharmacokinetic Study in Healthy Males
This is a phase I PK study in healthy males.
- Trial name
- COMDOS1 (NCT03055936)
- Testing
- Levodopa, Carbidopa, ODM-104
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Healhty
A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants
WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy…
- Trial name
- NCT07442591
- Testing
- Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.